Mifepristone

Definition and stakes

Thomas Owen Rice,  Washington v. U.S. Food and Drug Administration (2023)

“ In 2019, FDA approved a different manufacturer’s abbreviated NDA for a generic version of mifepristone and established the Mifepristone REMS Program, which covered both Mifeprex and the generic drug. Id. at 32, ¶ 103; ECF No. 51-3. In May 2020, American College of Obstetricians and Gynecologists (“ACOG”) sued FDA, challenging the Mifepristone REMS Program’s in-person dispensing requirement in light of the COVID-19 pandemic. ”
Source: Wikisource

U.S.C.A. 5th Cir.,  Alliance for Hippocratic Medicine v… (2023)

“ We disagree because FDA’s own documents show that mifepristone bears no resemblance to ibuprofen. In the 2000 Approval, FDA imposed a “Black Box” warning on mifepristone. FDA requires “Black Box” warnings when a drug “may lead to death or serious injury.” 21 C.F.R. § 201.57 (c) (1) . In its 2000 Approval, FDA conditioned its approval of mifepristone on the inclusion of this “Black Box” warning:
FDA Add. 182. The 2016 Major REMS Changes relaxed many of the requirements for marketing and using mifepristone. But it retained this “Black Box” warning:
https://perma.cc/R56J-BHW4.
”
Source: Wikisource

Thomas Owen Rice,  Washington v. U.S. Food and Drug Administration (2023)

“ I. Preliminary Injunction Standard Plaintiffs, on behalf of themselves and as parens patriae in protecting the health and well-being of its residents, moves for a preliminary injunction “affirming FDA’s original conclusion that mifepristone is safe and effective, preserving the status quo by enjoining any actions by Defendants to remove this critical drug from the market, and enjoining the unnecessary and burdensome January 2023 restrictions.” ”
Source: Wikisource

Get perspective with Kwize: daily news enlightened by great literature